Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group..

J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384.

PMID:
26679250
2.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration..

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3.

3.

Diphtheria, tetanus, poliomyelitis, yellow fever and hepatitis B seroprevalence among HIV1-infected migrants. Results from the ANRS VIHVO vaccine sub-study.

Mullaert J, Abgrall S, Lele N, Batteux F, Slama LB, Meritet JF, Lebon P, Bouchaud O, Grabar S, Launay O; ANRS VIHVO Study Group..

Vaccine. 2015 Sep 11;33(38):4938-44. doi: 10.1016/j.vaccine.2015.07.036.

PMID:
26209841
4.

Cryptococcosis Serotypes Impact Outcome and Provide Evidence of Cryptococcus neoformans Speciation.

Desnos-Ollivier M, Patel S, Raoux-Barbot D, Heitman J, Dromer F; French Cryptococcosis Study Group..

MBio. 2015 Jun 9;6(3):e00311. doi: 10.1128/mBio.00311-15.

5.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group..

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809.

6.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167.

7.

Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey.

Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, Gueit I, Mortier E, Costagliola D, Morlat P, Chêne G, Cacoub P; Mortalité 2010 and GERMIVIC study groups..

HIV Med. 2015 Apr;16(4):230-9. doi: 10.1111/hiv.12204.

PMID:
25522874
8.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups.; SILCAAT Scientific Committee..

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

9.

T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infection.

Weiss L, Chevalier MF, Assoumou L, Didier C, Girard PM, Piketty C, Costagliola D, Rouzioux C; ANRS 116 SALTO Study Group..

AIDS. 2014 Jul 17;28(11):1683-7. doi: 10.1097/QAD.0000000000000319.

PMID:
24841127
10.

Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native country.

Abgrall S, Fugon L, Lélé N, Carde E, Bentata M, Patey O, Khuong MA, Spire B, Bouchaud O, Carrieri P; ANRS-VIHVO study group..

Int J STD AIDS. 2014 Apr;25(5):389-90. doi: 10.1177/0956462413506894. No abstract available.

PMID:
24667876
11.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group.; ESPRIT Study Group.; SILCAAT Scientific Committee..

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978.

12.

Lack of effect of doxycycline on trough concentrations of protease inhibitors or non-nucleoside reverse transcriptase inhibitors in HIV-infected patients.

Abgrall S, Le Bel J, Lele N, Laouénan C, Eychenne N, Mentré F, Peytavin G, Bouchaud O; Vihvo Study Group..

HIV Clin Trials. 2013 Nov-Dec;14(6):313-8. doi: 10.1310/hct1406-313.

PMID:
24334184
13.

Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study.

Legeai C, Vigouroux C, Souberbielle JC, Bouchaud O, Boufassa F, Bastard JP, Carlier R, Capeau J, Goujard C, Meyer L, Viard JP; ANRS-COPANA Cohort Study Group..

PLoS One. 2013 Sep 18;8(9):e74868. doi: 10.1371/journal.pone.0074868.

14.

Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.

Assoumou L, Katlama C, Viard JP, Bentata M, Simon A, Roux C, Kolta S, Costagliola D, Rozenberg S; ANRS Osteovir study group..

AIDS. 2013 Sep 24;27(15):2425-30. doi: 10.1097/QAD.0b013e32836378c3.

PMID:
24029735
15.

Visiting one's native country: the risks of nonadherence in HIV-infected sub-Saharan migrants--ANRS VIHVO study.

Abgrall S, Fugon L, Lélé N, Carde E, Bentata M, Patey O, Khuong MA, Spire B, Carrieri P, Bouchaud O.

J Int Assoc Provid AIDS Care. 2013 Nov-Dec;12(6):407-13. doi: 10.1177/2325957413488181.

PMID:
23697775
16.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group..

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249.

17.

Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).

Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group..

Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12.

18.

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group..

J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455.

19.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC)..

Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164.

20.

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.

Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D; ANRS CO5 HIV-2 Cohort..

AIDS. 2013 Jan 2;27(1):69-80. doi: 10.1097/QAD.0b013e32835a10d8.

PMID:
23018441
Items per page

Supplemental Content

Loading ...
Support Center